03 May 2022 | News
Over 24 million cases of whooping cough per year world-wide
Intravacc B.V., located at Utrecht Science Park Bilthoven in the Netherlands, has announced the signing of an exclusive licensing agreement with Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd in China for Avacc 3 an OMV-based whooping cough vaccine.
Under the terms of this agreement Zhifei Lvzhu will receive an exclusive license for the Chinese territory and non-exclusive for Africa, South America and selected Asian countries. Under the agreement Intravacc will receive milestone and upfront payments and royalties over net sales. Both parties will continue to collaborate to tailor the Avacc 3 concept vaccine for the respective territories, including upscaling, toxicology and clinical trials.
Intravacc's Avacc 3, a homologous Bordetella pertussis candidate vaccine based on Intravacc's OMV platform, induces a strong systemic immune response. When administrated intranasally, it induces both a strong systemic and a strong mucosal immune response. Intravacc has designed and developed a platform based on outer membrane vesicles (OMVs) - spherical particles with intrinsic adjuvant properties. The OMVs can be rigged with immunogenic peptides and/or proteins that stimulate effective adaptive immunity